Articles & Presentations
IMS works with a variety of media outlets and trade associations to share expertise on issues impacting the pharmaceutical industry. This section provides abstracts and PDFs of current published articles, as well as extracts from recent industry presentations.
More Than a Game of Keep-Away
In this Pharmaceutical Executive report, Robert Hunkler, director of Professional Relations, IMS, discusses the full details of the AMA PDRP saga.
May 2, 2006
Keeping Pace
Many things in 2005 held steady: Seventeen products achieved block-buster status, the same number as in 2004; Pfizer topped the list; and many trends continued--consolidation increased, double-digit growth occurred in developing markets, and biologics grew more than twice as fast as the overall market.
May 1, 2006
Using Anonymous Patient-Level Information to Inform the Brand-Planning Process: Part 2
Anonymous patient-level data can be a critical component to the performance evaluation process, as it allows brand teams to better align performance metrics with strategic objectives and identify issues and opportunities earlier on, so they can take corrective action sooner and keep brand performance on track.
May 1, 2006
Using Anonymous Patient-Level Information to Inform the Brand-Planning Process: Part 1
Aggregated health care utilization information can be used to create a situational assessment and uncover potential opportunities to maximize brand utilization.
Apr 1, 2006
Assessing the Effect of Physician Treatment Decisions on Health Care Costs
Decisions made by physicians regarding diabetes treatment have a substantial effect on the burden of illness to payers and providers.
Feb 1, 2006
Using Anonymous Patient-Level Insights to Develop and Deliver Differential Messaging for Multi-indication Brands
The ability to deliver the right message to the right physician is critical, especially for multi-indication brands.
Jan 1, 2006
The Long and Winding Road Ahead: Medicare Part D, Post 2006
In this IMS report, Jon Resnick, Cambridge Pharma Consultancy, a Unit of IMS, discusses the impact of Medicare Part D in the pharmaceutical marketplace.
Jan 1, 2006
Re-channeling Promotional Spend: Fresh Approaches to Optimizing the Marketing Mix
When a blockbuster product went off patent at one of the world’s top pharmaceutical organizations, the company’s marketing team turned to IMS to help them gain market share with new products in new therapeutic classes.
Dec 9, 2005
Assessing the Effects of Medicare Drug Coverage on Chronic Disease Treatments
Anonymous patient-level insights can be used to assess the cost implications of the new Medicare part D prescription drug benefit for patients with chronic illnesses.
Dec 7, 2005
A New Era in Promotion Management: Adding Greater Certainty to the ROI Equation
It wasn't all that long ago when pharmaceutical marketers concerned themselves with two primary challenges: effectively deliver promotional messages through the sales force and ensuring the value and integrity of sampling programs.
Nov 15, 2005
|
| 
more
